Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | HTT | P42858 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.46 |
| ▸ | XBP1 | P17861 | 4/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735556 | 0.78 | ALDH1A1 (0.51) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL38652260 | 0.73 | NPC1 (0.38) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4292263 | 0.72 | NPC1 (0.50) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25755572 | 0.72 | GPR139 (0.32) | BPTFHTR2AHTR2C | |
| SCHEMBL10366228 | 0.69 | BPTF (0.40) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13323939 | 0.69 | SMN1; SMN2 (0.38) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9233774 | 0.68 | SMN1; SMN2 (0.50) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9234085 | 0.68 | BPTF (0.48) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1890748 | 0.67 | PDE1C (0.34) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20155367 | 0.67 | CREBBP (0.34) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718612-B2 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-5098900-A | Reducing contractions in smooth muscles | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-5011839-A | Antagonists to slow reacting substance of anaphylaxis | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0376079-A1 | 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| US-4783462-A | 3(2H)pyridazinone, and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0193853-A2 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | PRSS1, SPINT2, TMPRSS4 | ALDH1A1 975/4885NPC1 322/4885MAPT 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.